Role of new signalling pathways in cancer cell proliferation, survival and immunosuppression.
Preclinical development of protein kinase inhibitors that senstize solid tumors to chemotherapy and immunotherapy.
Preclinical and clinical development of drugs that modulate cellular autophagy and endoplasmic reticulum (ER) stress, as new strategies to tackle cancer.
Targeting MEK5-ERK5 pathway to improve the prognostic of neuroblastoma, a paediatric tumor originating from neural crest-derived cells
MAP kinase ERK5 inhibitors as a tool to sensitize endometrial cancer to chemotherapy and immunotherapy.
Preclinical and clinical development of ABTL082, an ER stress and autophagy inducer that sensitizes lung, endometrial and pancreatic cancers to chemotherapy and immunotherapy
PID2019-107561RB-I00 (funded by MICIU/AEI/10.13039/501100011033)
PID2022-136391OB-I00 (MICIU/AEI /10.13039/501100011033 and FEDER, UE)
